These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 11437671)

  • 1. Potential adverse effects of cyclooxygenase-2 inhibition: evidence from animal models of inflammation.
    Colville-Nash PR; Gilroy DW
    BioDrugs; 2001; 15(1):1-9. PubMed ID: 11437671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual acting anti-inflammatory drugs: a reappraisal.
    Bertolini A; Ottani A; Sandrini M
    Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-2: a therapeutic target.
    Turini ME; DuBois RN
    Annu Rev Med; 2002; 53():35-57. PubMed ID: 11818462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclooxygenase isoenzymes and newer therapeutic potential for selective COX-2 inhibitors.
    Kulkarni SK; Jain NK; Singh A
    Methods Find Exp Clin Pharmacol; 2000 Jun; 22(5):291-8. PubMed ID: 11031730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs).
    Wallace JL
    Am J Med; 1999 Dec; 107(6A):11S-16S; discussion 16S-17S. PubMed ID: 10628589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclooxygenase enzymes as targets for therapeutic intervention in inflammation.
    Colville-Nash PR; Gilroy DW
    Drug News Perspect; 2000 Dec; 13(10):587-97. PubMed ID: 12879130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical application of cyclooxygenase-2 inhibitors].
    Dzielska-Olczak M; Olczak S
    Pol Merkur Lekarski; 2001 Jun; 10(60):480-2. PubMed ID: 11503270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers.
    Brzozowski T; Konturek PC; Konturek SJ; Sliwowski Z; Pajdo R; Drozdowicz D; Ptak A; Hahn EG
    Microsc Res Tech; 2001 Jun; 53(5):343-53. PubMed ID: 11376495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety and potential clinical roles of the COX-2-specific inhibitors.
    van der Bijl P; van der Bijl P
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):17-22. PubMed ID: 14552700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclooxygenase-2 inhibitors: promise or peril?
    Mengle-Gaw LJ; Schwartz BD
    Mediators Inflamm; 2002 Oct; 11(5):275-86. PubMed ID: 12467519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview.
    Famaey JP
    Inflamm Res; 1997 Nov; 46(11):437-46. PubMed ID: 9427063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclooxygenase-2--10 years later.
    Hinz B; Brune K
    J Pharmacol Exp Ther; 2002 Feb; 300(2):367-75. PubMed ID: 11805193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Specific cyclooxygenase-2 inhibitors. Basis and options of a pharmacotherapeutic concept].
    Hinz B; Brune K
    Anaesthesist; 2000 Nov; 49(11):964-71. PubMed ID: 11151817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing.
    Jones MK; Wang H; Peskar BM; Levin E; Itani RM; Sarfeh IJ; Tarnawski AS
    Nat Med; 1999 Dec; 5(12):1418-23. PubMed ID: 10581086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
    Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
    J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inducible cyclooxygenase may have anti-inflammatory properties.
    Gilroy DW; Colville-Nash PR; Willis D; Chivers J; Paul-Clark MJ; Willoughby DA
    Nat Med; 1999 Jun; 5(6):698-701. PubMed ID: 10371510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COX-2 inhibition, H. pylori infection and the risk of gastrointestinal complications.
    Chan FK
    Curr Pharm Des; 2003; 9(27):2213-9. PubMed ID: 14529402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with cyclooxygenase-2 inhibitors.
    van Ryn J; Pairet M
    Inflamm Res; 1999 May; 48(5):247-54. PubMed ID: 10391112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Case report: reversible acute renal failure following therapy with both ketorolac (non-selective non-steroidal anti-inflammatory drug NSAID) and celecoxib (COX-2 selective) in the same patient].
    Galli G; Panzetta G
    G Ital Nefrol; 2002; 19(2):199-203. PubMed ID: 12195419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclo-oxygenase-2 inhibitors and the kidney: a case for caution.
    Noroian G; Clive D
    Drug Saf; 2002; 25(3):165-72. PubMed ID: 11945113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.